The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
An article from
Dive Brief
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
Published Aug. 26, 2026
Getty Images
Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data
This Top 4% Biotech Is Plunging; Why Analysts Aren't Sweating
Why Is Spyre Therapeutics Stock tumbling Today? - Spyre Therapeutics (NASDAQ:SYRE)
Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
Spyre deprioritizes anti-TL1A drug SPY072 in RA after Phase 2 misses its bar; shares dip 12% as SKYLINE UC data nears in…
Spyre Therapeutics took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage…
Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy missed internal priority…
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock…
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted…
